NCT06452160View on ClinicalTrials.gov

A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
MesotheliomaEpithelioid Hemangioendothelioma(EHE)Solid Tumor
Interventions
DRUG

BGC515

Capsules for oral administration

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

BridGene Biosciences Inc.

INDUSTRY